Prognosis of ductal adenocarcinoma of pancreatic head with overexpression of CD44
(Group B; n = 53) were compared. Results: Clinical data, cell types of tumors, and tumor staging between the two groups showed no significant differences. The 3-and 5-year survival rates were, respectively, 51.5% and 19.8% in patients with CD44
-tumor cells and 4.0% and 2.0% in those with CD44 + tumor cells. The differences were statistically significant (p < 0.0001). The median overall survival times of the two groups were also different (36.9 months vs. 12.2 months, p < 0.0001). Multivariate analysis showed that the CD44 as well as lymph node status, and differentiation of tumor cells were prognostic factors for patients with PDAC.
Conclusion:
The results suggested that CD44 expression in patients with PDAC after surgery was significantly associated with decreased survival, whereas patients with CD44 -tumor cells survived significantly longer.
